Search results
Showing 1231 to 1245 of 1364 results for social care
Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)
Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making
ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)
NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot
Discontinued Reference number: GID-TA10499
Discontinued Reference number: GID-TA10841
Discontinued Reference number: GID-TA10739
Discontinued Reference number: GID-TA10425
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
Discontinued Reference number: GID-TA10609
Discontinued Reference number: GID-TA10134
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
In development Reference number: GID-TA11277 Expected publication date: TBC
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
In development Reference number: GID-TA11117 Expected publication date: TBC
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)
Evidence-based recommendations on asciminib (Scemblix) for chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors.
NICE has developed a medtech innovation briefing (MIB) on VAAFT for treating anal fistulae .
In development Reference number: GID-TA10747 Expected publication date: TBC